Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$55.0 million.

  • Tg Therapeutics' Net Cash Flow fell 14873.75% to -$55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.7 million, marking a year-over-year decrease of 37086.33%. This contributed to the annual value of $87.0 million for FY2024, which is 102930.87% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Net Cash Flow is -$55.0 million, which was down 14873.75% from -$3.0 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Net Cash Flow ranged from a high of $112.9 million in Q3 2024 and a low of -$113.2 million during Q1 2022
  • Its 5-year average for Net Cash Flow is -$25.2 million, with a median of -$37.2 million in 2022.
  • As far as peak fluctuations go, Tg Therapeutics' Net Cash Flow tumbled by 108302.39% in 2021, and later surged by 24484.28% in 2023.
  • Quarter analysis of 5 years shows Tg Therapeutics' Net Cash Flow stood at -$27.6 million in 2021, then soared by 72.66% to -$7.6 million in 2022, then plummeted by 667.56% to -$58.0 million in 2023, then surged by 72.53% to -$15.9 million in 2024, then tumbled by 245.57% to -$55.0 million in 2025.
  • Its last three reported values are -$55.0 million in Q3 2025, -$3.0 million for Q2 2025, and -$47.8 million during Q1 2025.